Show simple item record

dc.contributor.authorImmink, Maarten M
dc.contributor.authorBekker, Mireille N
dc.contributor.authorde Melker, Hester E
dc.contributor.authorRots, Nynke Y
dc.contributor.authorSanders, Elisabeth A M
dc.contributor.authorvan der Maas, Nicoline A T
dc.date.accessioned2021-09-21T12:27:34Z
dc.date.available2021-09-21T12:27:34Z
dc.date.issued2021-09-03
dc.identifier.pmid34479491
dc.identifier.doi10.1186/s12879-021-06559-w
dc.identifier.urihttp://hdl.handle.net/10029/625273
dc.description.abstractMaternal immunization confers passive immunity to the fetus by transplacental antibody transfer. Infants may be better protected against pertussis if the mother received a diphtheriae, tetanus and acellular pertussis (Tdap) vaccination in the second trimester of pregnancy compared to the third trimester. This study evaluates IgG antibody concentrations in term and preterm infants at birth and 2 months after birth after maternal Tdap-vaccination between 200 and 240 w of gestation vs third trimester Tdap-vaccination. Further aims are assessing the determinants that underlie acceptance of second trimester maternal Tdap-vaccination as well as the tolerability of vaccination.en_US
dc.language.isoenen_US
dc.rights© 2021. The Author(s).
dc.subjectAcceptanceen_US
dc.subjectImmunogenicityen_US
dc.subjectMaternal immunizationen_US
dc.subjectPertussisen_US
dc.subjectPrematurityen_US
dc.subjectTolerabilityen_US
dc.subjectVaccinationen_US
dc.titleStudy protocol of the PIMPI-project, a cohort study on acceptance, tolerability and immunogenicity of second trimester maternal pertussis immunization in relation to term and preterm infants.en_US
dc.typeArticleen_US
dc.identifier.eissn1471-2334
dc.identifier.journalBMC Infect Dis 2021; 21(1):897en_US
dc.source.journaltitleBMC infectious diseases
dc.source.volume21
dc.source.issue1
dc.source.beginpage897
dc.source.endpage
dc.source.countryNetherlands
dc.source.countryEngland


This item appears in the following Collection(s)

Show simple item record